A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AGA2115 in Adult Healthy Volunteers
Latest Information Update: 13 Jan 2025
At a glance
Most Recent Events
- 10 Jan 2025 Status changed from recruiting to completed.
- 03 Apr 2024 The protocol has been amended to change in inclusion criteria now only Healthy subjects included with part A and B with reduction in patient population with respective age criteria.
- 03 Apr 2024 Planned number of patients changed from 96 to 72.